Concepedia

Publication | Open Access

Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study

DOIFull Paper Access

63

Citations

22

References

2017

Year

Jaren W. Landen, Niels Andreasen, Carol Cronenberger, Pamela F. Schwartz, Anne Börjesson‐Hanson, Henrik Östlund, Catherine Sattler, Brendon Binneman, Martin M. Bednar
Alzheimer s & Dementia Translational Research & Clinical Interventions

Abstract

Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.

References

YearCitations

Page 1